Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo

• Published in: Malaria Journal
• Main Authors: Laurencie Massamba, Marylin Madamet, Nicolas Benoit, Alicia Chevalier, Isabelle Fonta, Véronique Mondain, Pierre-Yves Jeandel, Rémy Amalvict, Pascal Delaunay, Joel Mosnier, Pierre Marty, Christelle Pomares, Bruno Pradines
• Format: Article in Journal/Newspaper
• Language: English
• Published: BMC 2020
• Subjects: Malaria; Plasmodium falciparum; Anti-malarial drug; Resistance; In vitro; Atovaquone; Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic; Noire; Pointe Noire; Traveller
• Online Access: https://doi.org/10.1186/s12936-020-3126-y; https://doaj.org/article/aebd4c58307d4fd8a95692a15eb47b67

Abstract Background The drug combination atovaquone–proguanil, is recommended for treatment of uncomplicated falciparum malaria in France. Despite high efficacy, atovaquone–proguanil treatment failures have been reported. Resistance to cycloguanil, the active metabolite of proguanil, is conferred by...